Zobrazeno 1 - 10
of 48
pro vyhledávání: '"Jin-Yi Zhu"'
Autor:
Li Zhang, Hui-Juan Liu, Ping Li, Yi Liu, Ting Zhang, Jin-Yi Zhu, Hong-Mei Zhu, Ya-Ping Zhou, Hai-Jun Wang, Yan Li
Publikováno v:
International Breastfeeding Journal, Vol 19, Iss 1, Pp 1-10 (2024)
Abstract Background Limited research has explored the associations of gestational age (GA) and breastfeeding practices with growth and nutrition in term infants. Methods This multicenter cross-sectional study recruited 7299 singleton term infants fro
Externí odkaz:
https://doaj.org/article/ba290b9148854109b6d00426dd6781b4
Publikováno v:
Case Reports in Pediatrics, Vol 2024 (2024)
Benign familial infantile seizure (BFIS) is an autosomal dominant infantile-onset epilepsy syndrome with a typically benign prognosis. It is commonly associated with heterozygous mutations of the PRRT2 gene located on chromosome 16p11.2. The frameshi
Externí odkaz:
https://doaj.org/article/3c6751bae8d3475ca26f662182962dcc
Autor:
Bryce K. Allen, Saurabh Mehta, Stuart W. J. Ember, Jin-Yi Zhu, Ernst Schönbrunn, Nagi G. Ayad, Stephan C. Schürer
Publikováno v:
ACS Omega, Vol 2, Iss 8, Pp 4760-4771 (2017)
Externí odkaz:
https://doaj.org/article/8df1dfe0be9542f4a9457d8f0863abea
Autor:
Sanne H. Olesen, Donna J. Ingles, Jin-Yi Zhu, Mathew P. Martin, Stephane Betzi, Gunda I. Georg, Joseph S. Tash, Ernst Schönbrunn
Publikováno v:
Molecules, Vol 20, Iss 1, Pp 1643-1660 (2015)
The molecular chaperone Hsp90 is regulated by co-chaperones such as p50Cdc37, which recruits a wide selection of client protein kinases. Targeted disruption of the Hsp90-p50Cdc37 complex by protein–protein interaction (PPI) inhibitors has emerged a
Externí odkaz:
https://doaj.org/article/00296e6254394b5caf006653751a6a7c
Autor:
Ernst Schönbrunn, Nicholas J. Lawrence, Gary W. Reuther, Harshani R. Lawrence, Cyril H. Benes, Conor C. Lynch, Patricia Greninger, Paula J. Cranfill, Jin-Yi Zhu, Marilena Tauro, Muhammad Ayaz, Steven Gunawan, Norbert Berndt, Que T. Lambert, Stuart W. Ember
Table S1: Crystallographic data collection and refinement statistics Table S2: Inhibitory activity against other BET bromodomains Table S3: Bromodomain profiling data Fig. S1: Detailed binding interactions of compounds 1 - 5 in BRD4-1 Fig. S2: Compar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b3a8658e8c0c794a279fbf75d3faea43
https://doi.org/10.1158/1535-7163.22504383.v1
https://doi.org/10.1158/1535-7163.22504383.v1
Autor:
Ernst Schönbrunn, Nicholas J. Lawrence, Gary W. Reuther, Harshani R. Lawrence, Cyril H. Benes, Conor C. Lynch, Patricia Greninger, Paula J. Cranfill, Jin-Yi Zhu, Marilena Tauro, Muhammad Ayaz, Steven Gunawan, Norbert Berndt, Que T. Lambert, Stuart W. Ember
Synergistic action of kinase and BET bromodomain inhibitors in cell killing has been reported for a variety of cancers. Using the chemical scaffold of the JAK2 inhibitor TG101348, we developed and characterized single agents which potently and simult
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::174289931beab104a62e35bd2bf1cb33
https://doi.org/10.1158/1535-7163.c.6537717.v1
https://doi.org/10.1158/1535-7163.c.6537717.v1
Autor:
Ernst Schönbrunn, Nicholas J. Lawrence, Gary W. Reuther, Harshani R. Lawrence, Cyril H. Benes, Conor C. Lynch, Patricia Greninger, Paula J. Cranfill, Jin-Yi Zhu, Marilena Tauro, Muhammad Ayaz, Steven Gunawan, Norbert Berndt, Que T. Lambert, Stuart W. Ember
Table S4: Kinome profiling data (Microsoft Excel sheet) Table S5: Cell line screening data (Microsoft Excel sheet)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::229255a872f5f91718071196e1a1a877
https://doi.org/10.1158/1535-7163.22504377.v1
https://doi.org/10.1158/1535-7163.22504377.v1
Autor:
Edmond R. Watson, Scott J. Novick, Mary E. Matyskiela, Philip P. Chamberlain, Andres Hernandez de la Peña, Jin-Yi Zhu, Eileen Tran, Patrick R. Griffin, Ingrid E. Wertz, Gabriel C. Lander
Cereblon (CRBN) is an ubiquitin ligase (E3) adaptor protein co-opted by CRBN E3 Ligase Modulatory Drugs (CELMoD) agents that target therapeutically-relevant proteins for degradation. Prior crystallographic studies defined the drug-binding site within
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6725d3acc0caf347d97d1c4f855d6401
https://doi.org/10.1101/2022.07.02.498551
https://doi.org/10.1101/2022.07.02.498551
Publikováno v:
J Med Chem
Inhibition of the bromodomain containing protein 9 (BRD9) by small molecules is an attractive strategy to target mutated SWI/SNF chromatin-remodeling complexes in cancer. However, reported BRD9 inhibitors also inhibit the closely related bromodomain-
Autor:
Kwon Ho Hong, David C. Mikles, Alex S. Goldstein, Gunda I. Georg, John K. Amory, Ernst Schönbrunn, Yan Chen, Jin-Yi Zhu
Publikováno v:
ACS Chemical Biology. 13:582-590
Enzymes of the ALDH1A subfamily of aldehyde dehydrogenases are crucial in regulating retinoic acid (RA) signaling and have received attention as potential drug targets. ALDH1A2 is the primary RA-synthesizing enzyme in mammalian spermatogenesis and is